Key takeaways
- DGL is a licorice extract with glycyrrhizin reduced or removed. The name does not establish a uniform composition or zero residual glycyrrhizin (Licorice safety distinction; Specific residual rule).
- GutGard is one flavonoid-rich proprietary preparation. Its trials cannot establish that all DGL tablets, teas or blends work alike (Tested extract; Different reported specification).
- Positive dyspepsia and reflux trials have manufacturer involvement. A dependable, independently established digestive benefit remains unproven under this review’s funding screen (Company authors and randomization; Sponsor disclosure).
- Older ulcer trials include null results and multi-ingredient products. A DGL-containing antacid combination cannot establish the effect of DGL alone (Null original; Combination trial).
- DGL has not been independently established as a replacement for H. pylori eradication treatment, ulcer care or reflux medicines (On-treatment tests; Combination comparison; Cause-directed treatment).
- Reducing glycyrrhizin addresses an important source of licorice toxicity, but does not establish complete cardiovascular or medication safety for every product (Glycyrrhizin warnings; Limited interaction experiment).
DGL has a plausible rationale and encouraging short-term results for the proprietary extract GutGard. Major positive studies have commercial involvement; other studies use different extracts or combinations and leave financial gaps. The finite evidence reviewed here does not establish a generalizable independently financed digestive benefit. Symptoms, ulcer healing and durable eradication are separate outcomes. Reduced glycyrrhizin does not guarantee complete product or medication safety, and funding concerns do not prove ineffectiveness (Small dyspepsia trial; Short reflux trial; On-treatment infection study; Safety boundary).
Contents
Evidence summary · What it is · Forms and delivery · How it works · Hype versus evidence · Benefits by claim · What works · Risks · Interactions · Who should avoid · Research regimens · Laboratory evidence · Funding and access · Regulation · FAQs · Sources
Evidence summary
The strength column concerns the exact claim after conflict screening. Commercial outcome studies are retained as context, including their favorable findings, but excluded from the independent benefit basis. Unknown funding or purchasing arrangements remain unknown.
| Claim | Evidence | Source | Funding or conflict | Strength |
|---|---|---|---|---|
| Relieves functional dyspepsia | Positive small placebo-controlled GutGard trial | Raveendra 2012 | Manufacturer authors and company-run randomization | Insufficient independent evidence |
| Relieves reflux symptoms | Positive short GutGard trial; analysis and follow-up limitations | Raj 2025 | Natural Remedies sponsorship; conflicting reports of sponsor design involvement | Insufficient independent evidence |
| Heals gastric ulcers | Older placebo-controlled studies include null findings | Engqvist 1973; Bardhan 1978 | Cedona supplied Engqvist capsules; Boehringer supplied Bardhan active/placebo. Cash and purchase/donation terms unreported | Inconsistent historical context; no established independent benefit |
| Works as well as ulcer medicines | Historical Caved-S comparison without a significant healing difference | Morgan 1982 | Funding unresolved; combination formulation | Does not establish DGL-alone equivalence |
| Eradicates H. pylori by itself | Positive on-treatment test changes with GutGard | Puram 2013 | NICS financing and Natural Remedies authors | Independent durable eradication not established |
| Improves H. pylori treatment | Small Iranian add-on or substitution trials | Momeni 2014; Hajiaghamohammadi 2016 | Public support in Momeni; procurement and other funding gaps | Preliminary, product-specific combination evidence |
| Licorice plus a probiotic improves infection or digestive symptoms | No significant between-group advantage on key measures | Yoon 2019 | No funding declared; commercial study-product development and procurement unresolved | Does not establish standalone DGL benefit |
| Has no drug interactions | Limited four-enzyme human study | Liu 2023 | NIH-funded; source extract from Natural Remedies, transaction terms unresolved | Cannot support a universal safety claim |
What it is
Licorice, also spelled liquorice, comes from plants in the genus Glycyrrhiza. Commercial materials can involve different species, roots, underground stems and extraction processes. Chemical profiling can distinguish major species and measure several constituents; the plant name alone is an incomplete product specification. Li’s analytical study
Deglycyrrhizinated licorice describes processing intended to reduce glycyrrhizin, also called glycyrrhizic acid. Glycyrrhizin is a sweet-tasting saponin associated with licorice’s important electrolyte and blood-pressure risks. A reduced-glycyrrhizin extract can still contain biologically active flavonoids and other compounds. Removing one component does not make the remaining mixture pharmacologically inert. NCCIH licorice overview
This article concerns oral DGL and closely relevant reduced-glycyrrhizin extracts used for digestive claims. It does not transfer findings from licorice mouthwashes, skin preparations or unrelated indications to the stomach or bowel.
Forms and delivery
| Preparation | What distinguishes it | Why it matters |
|---|---|---|
| Whole licorice root, ordinary extract or tea | Glycyrrhizin has not necessarily been reduced | It cannot inherit DGL’s proposed safety advantage (Glycyrrhizin distinction). |
| Generic DGL powder, chewable or capsule | Extraction, flavonoid content and residual glycyrrhizin can differ | Milligrams of different extracts are not automatically equivalent (Chemical variability; Specific characterized extract). |
| GutGard | Proprietary G. glabra extract standardized for flavonoids | Evidence initially belongs to the preparation actually tested (Original specification; Commercial identity). |
| D-Reglis | Named Iranian licorice product used in combination-treatment trials | Older gastrointestinal reports do not adequately specify the tested batch’s residual glycyrrhizin (Named product; Named product with batch gap). |
| Caved-S | Historical DGL-containing preparation with additional active ingredients | Results cannot be assigned entirely to DGL; historical formulations also changed (Historical changing composition; Original ingredient table). |
| DGL plus probiotics, antacids or other ingredients | More than one active intervention | A combination result does not identify which component helped (Mixed intervention; Antacid combination). |
| Glycyrrhizin or glycyrrhetinic acid | Specific licorice constituents rather than DGL | Their pharmacology and doses are different (Different licorice constituents). |
| Carbenoxolone | Chemically modified glycyrrhetinic-acid derivative used as an anti-ulcer drug | Prescription-drug evidence is not evidence for a DGL supplement (Primary chemical identity). |
NLM identifies carbenoxolone as glycyrrhetinic acid 3-O-hemisuccinate, a chemically modified derivative distinct from DGL. The 1983 Caved-S prescribing advertisement lists DGL with aluminium hydroxide, magnesium carbonate and sodium bicarbonate. The complete 1971 trial lists additional bismuth and frangula in its historical tablets. The exact April 1979 advertisement PDF was not recovered; the composition statement rests on the actual 1971 original. Ingredient records do not establish efficacy (NLM chemical record; Indexed 1983 prescribing record; Complete 1971 ingredient table; Unrecovered April 1979 advertisement).
A specification discrepancy that matters
The 2012 and 2013 GutGard papers specify glycyrrhizin at no more than 0.5% by weight. The 2025 reflux paper instead states no more than 3.0%, while the current manufacturer webpage states below 0.5%. These published descriptions are not identical. This audit could not establish whether the later figure reflects a specification change, a reporting error or another explanation. A current batch certificate would be needed to establish actual content. 2012 methods, 2013 methods, 2025 methods, manufacturer specification
Useful product information includes the botanical species, extraction process, extract amount, measured residual glycyrrhizin, other active ingredients and batch testing. “Natural,” “clinical grade” and a trademark do not substitute for those details or demonstrate clinical benefit.
How it works
Proposed digestive actions include effects on mucus or mucosal protection, inflammatory signaling and bacterial activity. Much of this rationale comes from cell or animal experiments. For example, GutGard research in infected rodents examined gastric bacterial colonization; it did not test whether an adult taking a retail DGL tablet is cured of infection. Kim 2013 preclinical study
There are several distinct questions:
- Does the product reduce a person’s symptoms?
- Does an ulcer actually heal on objective examination?
- Is an infection durably eradicated after treatment ends?
- Does any benefit persist without unacceptable adverse effects?
Evidence for one does not answer the others. A lower breath-test measurement, an anti-inflammatory laboratory signal or a short-term symptom improvement cannot establish all four (Symptom endpoint without healing; On-treatment tests; Animal colonization).
The reason for reducing glycyrrhizin is also mechanistic: its metabolite can interfere with cortisol handling through 11β-HSD2, promoting mineralocorticoid-like effects. That helps explain the concern about sodium retention, potassium loss and blood pressure with glycyrrhizin-containing licorice. It does not identify a universal safe residual concentration for every person. Liu’s pharmacological context
Hype versus evidence
A positive branded trial does not validate the whole category. GutGard, generic DGL, whole root and a licorice-containing blend are different interventions. Shared plant ancestry is not a clinical equivalence test (Different chemical materials; Combination trial).
A review’s academic status does not erase a trial’s commercial links. The 2023 Cochrane review’s GutGard result comes from one small trial. Its study table records funding and conflicts as unavailable, yet also records company-generated randomization. The original paper supplies the manufacturer affiliations. Cochrane review
A “phase III” title does not itself mean a medicine has regulatory approval. Approval is a separate legal determination. Likewise, “no conflicts declared” is not equivalent to “no commercial support.” (Original title and funding; Regulatory distinction).
“No side effects” or “no interactions” exceeds the evidence. The current Natural Remedies page promotes long-term safety and absence of clinically relevant drug interactions. AIDP’s dated May 2023 sheet markets barrier, motility and immunity benefits and describes the dyspepsia trial as 15 days with a 30-day follow-up; the original actually treated participants for 30 days. These commercial statements cannot expand short, preparation-specific human results into general benefit or safety (Current manufacturer claims; Dated distributor sheet; Actual treatment duration; Narrow interaction conditions).
Failure to find a significant difference does not prove two treatments equivalent. An equivalence or non-inferiority claim needs an appropriate design and margin. A small, inconclusive comparison cannot establish that an herbal product safely replaces a medicine (No equivalence margin; Nonsignificant comparison).
Benefits by claim
Functional dyspepsia Insufficient independent evidence
Raveendra randomized 50 selected adults with functional dyspepsia, 25 per group, to GutGard 75 mg twice daily or placebo for 30 days. Symptoms and quality-of-life scores favored GutGard, but age and diastolic blood pressure differed at baseline. GERD and IBS were excluded. Seven authors were affiliated with Natural Remedies and the company generated randomization. The complete original does not identify a separate cash-funding budget or product purchase/donation terms. This remains a small commercially involved trial, not proof for all upper-digestive complaints (Original methods, tables and affiliations; Complete matching original).
Cochrane graded this single 50-person GutGard study as moderate-certainty evidence for short-term global symptoms and quality of life. That is the same Raveendra paper, not independent replication. The review reports university support in Chile and Germany, no external support and no known author conflicts; its editor-author did not participate in editorial decisions. Its study table leaves funding/conflicts unavailable but records company-generated randomization. Review-level disclosures do not erase the original manufacturer affiliations (Actual results, study chart and disclosures; Original author affiliations).
The practical research gap is an adequately powered, independently financed trial with a defined extract, clinically meaningful response threshold and longer follow-up. It should also establish which dyspepsia population was studied rather than treating all upper-abdominal symptoms as one diagnosis (Small selected trial limits; Single-trial synthesis).
Reflux and heartburn Insufficient independent evidence
Raj randomized 200 selected adults with mild-to-moderate reflux symptoms. Day-28 GERD-HRQL change favored GutGard after baseline adjustment; the unadjusted comparison did not. Only 78 active and 87 placebo participants contributed to that table; the modified intention-to-treat analysis did not impute missing observations. Gastric emptying, rescue use and rebound comparisons were nonsignificant. Natural Remedies sponsored the trial and supplied products. The funding statement reports sponsor design/protocol input, while the acknowledgments deny sponsor design involvement: the paper is internally inconsistent on that role. Medical-writing support is acknowledged without its payer, and authors declare no conflicts (Complete methods, results and declarations).
This is a worthwhile symptom signal, but it does not establish healing of erosive esophagitis, prevention of complications, benefit in severe disease or equivalence to acid-suppressing treatment. A questionnaire result and an objective disease outcome should not be merged into a “reflux cure” claim (Selected symptoms and unmeasured healing).
Gastric and duodenal ulcers Insufficient independent evidence
Engqvist enrolled 38 patients initially and studied 30 in the second four-week crossover period; DGL did not accelerate radiological gastric-ulcer healing. The Swedish team acknowledged Cedona’s capsule supply. Feldman and Gilat started 50 people and analyzed 47, finding symptom improvement in 12/23 versus 11/24 with Caved-S versus a matching preparation in which DGL was replaced. No objective ulcer-healing endpoint was reported. The Israeli team acknowledged Cedona’s tablet supply. Both complete originals were recovered, but cash financing and purchase/donation terms remain unreported. Neither is treated as financially cleared independent evidence (Engqvist original record; Complete Swedish paper; Feldman original record; Complete Israeli paper).
Bardhan randomized 96 people to two 500 mg DGL capsules five times daily or placebo for four weeks. It found no significant ulcer-healing or symptom advantage. The tested Ulcedal was prepared by Cedona and marketed by Boehringer Ingelheim, which supplied active/placebo capsules; purchase/donation terms were not stated. One DGL participant developed edema and low potassium and had previously experienced edema with carbenoxolone. This is a reported event, not a DGL-wide causal rate. Earlier favorable studies are discussed critically in the paper, not independently replicated here (Original record; Complete original trial).
Morgan’s 1982 single-blind comparison entered 117 people and analyzed 100. Gastric ulcers healed in 60% versus 66% by six weeks and 88% versus 94% by twelve weeks with multi-ingredient Caved-S versus cimetidine; nonsignificance did not establish equivalence. Its cash and product terms were not reported. In 1985, 100 people were randomized to Caved-S or placebo added to ranitidine, without a healing or symptom advantage. Glaxo Group Research and Tillotson Laboratories supported trial operation, and Glaxo performed statistics; amounts and procurement terms were not itemized. Neither establishes that isolated DGL matches modern ulcer care (1982 original record; Complete 1982 paper; Complete 1985 add-on paper).
EMA’s revised assessment, published in July 2026, judged DGL ulcer evidence conflicting and affected by serious methodological limitations, insufficient for well-established medicinal use. Its assessment of the small dyspepsia trial was also cautious. This is regulatory appraisal of mixed underlying evidence, not a new independently funded trial. EMA 2026 assessment
H. pylori Insufficient independent evidence
Puram’s GutGard trial enrolled 107 people and analyzed 100 per protocol. At day 60, stool-antigen tests were negative in 56% versus 4%, and breath tests in 48% versus 2%. These were on-treatment assessments, without established durable post-treatment eradication. NICS in South Korea financed the project; Natural Remedies employees coauthored it. Its findings do not justify substituting DGL for eradication care. Puram 2013
Two Iranian studies require separate interpretation:
- Momeni 2014: 60 selected patients received antibiotic-containing regimens with D-Reglis 380 mg twice daily or bismuth. Breath tests four weeks after treatment were negative in 20/30 versus 17/30 (p=0.428). The trial had no equivalence margin, so nonsignificance does not show safe substitution. Shahrekord University’s Research Deputy supported the study and no author conflicts were declared. Product transaction terms, tested-batch glycyrrhizin and clearly stated regimen duration remain unresolved (Complete original methods and support).
- Hajiaghamohammadi 2016: D-Reglis 380 mg twice daily for two weeks was added to an antibiotic regimen, followed by continued omeprazole. Negative stool tests were 45/54 versus 35/56 (83.3% versus 62.5%, p=0.018). The narrative’s arm counts conflict with that outcome table, and testing timing and PPI washout are unclear. Authors declared no conflicts, but cash funding, product purchase/donation and batch glycyrrhizin were not reported. This is preliminary adjunct evidence, not DGL-alone eradication (Complete methods, table and declarations).
Yoon randomized 142 people and analyzed 128 per protocol after eight weeks of fermented milk containing a probiotic plus 100 mg reduced-glycyrrhizin licorice daily. Key between-group breath-test, symptom and quality-of-life comparisons were nonsignificant; only 2 versus 1 participants tested negative. Korea Yakult developed the study product. Authors declared no funding or conflicts, while material purchase/donation terms were not given. The original does not identify the extract as GutGard, and the mixture cannot establish a DGL-alone effect (Original methods, results and disclosures).
Testing after appropriate treatment is important because symptom relief does not establish that infection is gone. NIDDK describes cause-directed ulcer treatment and follow-up testing for H. pylori; it does not establish a DGL replacement regimen. NIDDK ulcer treatment
Intestinal barrier repair and general gut health Insufficient
The finite human studies reviewed here do not establish an independently replicated DGL treatment for IBS, constipation, inflammatory bowel disease or a broadly defined “leaky gut” condition. Animal colonization, short upper-digestive symptom scores and distributor mechanism claims do not establish those patient outcomes (Excluded animal experiment; Selected dyspepsia study; Commercial broad claims).
Claims about general barrier repair should specify the population, validated measurement and patient benefit. A manufacturer’s mechanism diagram or animal experiment cannot substitute for those clinical outcomes (Preclinical endpoints; Commercial mechanism claims).
What works and what does not
| Claim | Verdict | Main reason |
|---|---|---|
| A particular GutGard extract may relieve some upper-digestive symptoms | Promising commercial evidence; independent benefit unestablished | Short, sponsor-involved trials need independent replication (Specific positive symptoms; Specific positive symptoms). |
| All DGL products have the same effects | Unsupported | Species, extraction, composition and co-ingredients differ (Compositional distinction). |
| DGL reliably heals ulcers | Not independently established | Historical results are inconsistent and often formulation-specific (Null healing trial; Combination comparison). |
| DGL replaces H. pylori treatment | Unsupported | On-treatment suppression and combination studies do not establish a replacement (On-treatment endpoint; Actual eradication care). |
| DGL can be assumed equivalent to cimetidine or bismuth | Unsupported | Nonsignificance and multi-ingredient comparisons do not prove equivalence (Combination nonsignificance; No equivalence margin). |
| DGL repairs the gut microbiome or intestinal barrier generally | Not established in the audited human evidence | Mechanistic or commercial claims are broader than demonstrated outcomes (Animal, not patient outcome; Commercial claims). |
| Removing glycyrrhizin makes any product risk-free | Unsupported | Residual content, other constituents, dose, duration and medicines remain relevant (Safety boundary; Limited extract test). |
Risks and reported side effects
Safety findings need the same scrutiny as benefits. Short studies in selected adults cannot estimate uncommon serious events, establish lifelong use or settle pregnancy safety.
| Concern | What is known | Important limitation |
|---|---|---|
| Glycyrrhizin-related blood-pressure, potassium and fluid effects | Established concern with glycyrrhizin-containing licorice | The rate with a verified low-glycyrrhizin DGL product is not established here (Licorice warnings; Assessment limitations). |
| Headache, abdominal discomfort, vomiting, diarrhea, itching and electrolyte events | Raj recorded these events in its short trial; no serious events were reported | Hyperkalemia occurred in 5/97 active versus 6/97 placebo; hyponatremia in 1/97 versus 0/97. Recorded events do not prove causation (Original safety table). |
| Allergy to an ingredient | Prior hypersensitivity to the product or its ingredients matters | A reliable DGL-specific incidence estimate was not found (Hypersensitivity exclusions; Clinical assessment). |
| Long-term use | Evidence is much thinner than marketing often implies | Brief normal laboratory results cannot exclude delayed or rare harm (Qualified duration; Short follow-up). |
| Pregnancy, breastfeeding and children | DGL-specific clinical safety is insufficient | Ordinary licorice pregnancy findings cannot be converted into a precise DGL risk estimate (Pregnancy and lactation limits; Special populations). |
| Multi-ingredient products | Risks may come from antacids, botanicals, sweeteners or other additions | Safety of one extract does not establish safety of the whole formulation (Additional active ingredients; Mixed intervention). |
NCCIH warns that glycyrrhizin-related serious effects can occur particularly with prolonged or high exposure and in susceptible people, including those with heart or kidney conditions or hypertension. Its cautious statement that glycyrrhizin-free oral products might be safe for up to four months is not a verified safe-use limit for every “DGL” label. NCCIH
Raj’s safety table recorded hyperkalemia in 5/97 versus 6/97, hyponatremia in 1/97 versus 0/97, and several symptom events, with no serious events. Abdominal pain was 3/97 versus 13/97 (p=0.016), despite a general prose statement of no adverse-event difference. Bardhan’s older trial recorded edema and hypokalemia in one DGL participant with a previous reaction to carbenoxolone. These records neither establish DGL causation nor justify blanket cardiovascular or electrolyte reassurance (Actual Table4; Original adverse-event text).
Safety note: Vomiting blood or black, tarry stools requires urgent medical assessment. Food stuck in the oesophagus, especially inability to swallow saliva or manage secretions, needs urgent assessment; complete obstruction is an emergency. Persistent vomiting, worsening swallowing difficulty or unexplained weight loss also needs prompt assessment. Sudden persistent chest pain, or chest pain with breathlessness, sweating or spreading pain, requires emergency care rather than assuming heartburn (Bleeding warning signs; Food-obstruction guidance; Persistent warning symptoms; Chest-pain emergency guidance).
Interactions and evidence gaps
There is no validated complete interaction list for every DGL preparation. The table distinguishes licorice-related concerns from the much narrower DGL-specific evidence.
| Medicine or exposure | Why it matters | Evidence boundary |
|---|---|---|
| Potassium-losing diuretics, stimulant laxatives, corticosteroids or cardiac glycosides such as digoxin | Glycyrrhizin-associated electrolyte changes can add risk | Established licorice warning; magnitude for a particular reduced-glycyrrhizin product is unresolved (Electrolyte interactions). |
| Blood-pressure treatment | Licorice-related blood-pressure elevation could oppose treatment | Do not assume that a DGL label eliminates residual exposure (Blood-pressure interaction). |
| Medicines metabolized by CYP enzymes | Licorice constituents may affect drug handling | Limited human extract-specific data do not cover all enzymes, transporters or medicines (Four tested pathways and limits). |
| Anticoagulants | Whole-licorice case reports have inconsistent directions of effect | No dependable DGL-specific effect size or universal dose-adjustment rule (Case-report limitations). |
| Other licorice foods, teas or supplements | Glycyrrhizin exposure can come from several products | A low-glycyrrhizin capsule does not cancel exposure from other sources (Glycyrrhizin exposures). |
| PPIs, H2 blockers or antibiotics | Some digestive studies used combinations or excluded concurrent treatment | These designs do not establish that every coadministration is safe or useful (Combination design; Concurrent treatment exclusions). |
EMA’s licorice interaction assessment supports the electrolyte and blood-pressure concerns, while describing the limitations of anticoagulant reports. These warnings concern the preparations and exposures reviewed there; applying their exact risk to every DGL product would overstate the evidence. EMA interaction assessment, section 5.5.4
Liu enrolled 19 healthy peri/postmenopausal women and analyzed 14 completers after early pandemic termination. Each 75 mg capsule contained 0.55 mg glycyrrhizic acid and was taken twice daily for fourteen days. Average exposure to four probe drugs did not significantly change. The probes were given after an overnight fast, testing longer-lasting effects rather than short-lived simultaneous-use inhibition. NIH grants supported the study; Natural Remedies supplied the extract through the university center and Shimadzu provided the instrument, with transaction terms unspecified. The paper did not identify GutGard. These findings do not establish safety with every medicine, dose or product (Complete original methods, tables and disclosures).
The actual label and medication list need review together. The available evidence does not support a universal spacing interval or instructions to stop, substitute or adjust prescribed treatment (Label and professional review; Design limitations).
Who should avoid unsupervised use
Unsupervised use is particularly inappropriate when there is suspected bleeding, swallowing trouble, persistent unexplained symptoms, a known ulcer or confirmed H. pylori infection. A product that changes symptoms can leave the underlying cause untreated (Alarm symptoms; Cause-directed care).
People with hypertension, heart or kidney disease, low potassium, a previous reaction to licorice products or complex medication regimens need product-specific assessment. Pregnancy, breastfeeding and childhood also lack an established general DGL supplement regimen in this review. These precautions are not a claim that every chemically verified low-glycyrrhizin preparation has the same risk as whole licorice (Susceptibility and special populations; Assessed warnings).
Research regimens and formulation limits
These are research descriptions, not instructions for personal use. Different extracts cannot be compared by milligram weight alone. Neither a trial dose nor a brand’s serving size establishes an effective or safe regimen for another person or product (Specific research regimen; Different characterized product; Separate licensing conditions).
| Study or use | Studied preparation and amount | Duration | Interpretation |
|---|---|---|---|
| Functional dyspepsia | GutGard 75 mg twice daily | 30 days | Manufacturer-involved trial; Raveendra |
| Reflux symptoms | GutGard 75 mg twice daily after meals | 28 days | Sponsor-involved; selected mild-to-moderate symptoms (Raj original). |
| H. pylori monotherapy experiment | GutGard 150 mg once daily before breakfast | 60 days | Commercial on-treatment test changes, not proven durable eradication (Puram original). |
| Historical gastric-ulcer study | DGL 760 mg three times daily | Four-week periods | Null trial; Engqvist (Full capsule methods). |
| H. pylori adjunct study | D-Reglis 380 mg twice daily with a drug regimen | Two weeks | Batch specification and funding gaps; Hajiaghamohammadi |
| Probiotic/licorice milk | 100 mg licorice extract in a 150 mL combination drink daily | Eight weeks | Combination, not isolated DGL; Yoon |
| Drug-metabolism study | Standardized extract 75 mg twice daily | 14 days | Narrow interaction experiment, not treatment efficacy; Liu |
Historical chewable-product research and modern capsule trials do not establish that chewing is superior to swallowing an otherwise equivalent preparation. Canada’s specific licensing monograph does require chewable forms; that regulatory condition is described below. This audit did not find a convincing independent head-to-head test resolving the clinical comparison (Historical chewable protocol; Modern capsule protocol; Specific licensing rule).
Animal and in vitro evidence excluded from conclusions
Kim’s GutGard experiments used infected mice and gerbils. Korean KHIDI and NCEED support and no author conflicts were declared; manufacturer-product payment terms remained unreported. These colonization experiments supply a biological hypothesis and are excluded from human eradication conclusions (Complete original animal methods and disclosures).
Bhide’s 2022 safety report tested rats and included Natural Remedies R&D and regulatory-affairs authors. Its no-conflict declaration does not remove those affiliations. Animal tolerated doses are not converted here into a human safe dose, and the study is excluded from human safety conclusions. Bhide 2022
Laboratory evidence can help explain what to test next. It cannot establish relief, cure, prevention or an adverse-event rate in people. Human-derived cells outside the body also remain in vitro evidence.
Reported funding and access limits
Research funding at a glance
42 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
41 additional entries have no single explicit tier. Unclassified does not mean independent.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Who pays and who profits
Natural Remedies develops and sells GutGard. Its human-health site lists its Indian office in Bengaluru, a US office in Austin and manufacturing in Tamil Nadu, India. The company’s leadership page identifies Anurag Agarwal as managing director and Amit Agarwal as a director and former R&D leader. These are documented operating roles; they are not verified current equity percentages. Product and locations, company leadership
The current ultimate shareholding and trust-beneficiary chain could not be established from an accessible current primary ownership filing. Older company-return material is insufficient to establish the 2026 cap table. This review therefore does not assign an ownership percentage to a named individual or invent an outside investor.
CARE Ratings’ October 2025 credit report describes bank financing and loans from directors, relatives and other companies. It lists Natural Living as a wholly owned subsidiary at 31 March 2025. These are group financing facts, not evidence that any lender paid for a particular GutGard trial. CARE’s issuer-fee business model makes it an interested corporate source, even though credit-market accountability gives it reasons to report accurately. Credit report and fee disclosure
AIDP’s dated May 2023 sales sheet marketed GutGard. Its official corporate-office record identifies City of Industry, California. A May 2019 manufacturer-origin announcement called AIDP the exclusive North American distributor of its branded ingredients. These records do not establish current contractual exclusivity, royalties, equity ownership or specific research financing (Dated sales sheet; US corporate office; Historical manufacturer announcement).
NICS, identified as a Seoul company in the 2013 trial, financed that project and had a coauthor. Its current beneficial ownership and exact relationship to the manufacturer were not verified. Likewise, the audited papers identify Iran Darouk and Korea Yakult as product businesses, but do not settle their study procurement terms or current ownership chains.
Public and nonprofit sources were checked too
The Cochrane review reports university support and no known author conflicts. The UK charity’s 2024 accounts show that publication royalties from Wiley are its principal central revenue stream, with other products, events, consultancy and grants also contributing. Its policy restricts funding from businesses with a relevant health-topic interest. This supports a provisionally independent review-level classification, not automatic independence of every included trial. Review disclosures, Cochrane accounts and policy
NIH’s NCCIH receives congressional appropriations. Public financing of the 2023 interaction study is documented, but the original extract transaction remains unresolved. Public cash and commercial product sourcing are separate questions. NCCIH funding history, trial disclosures
EMA and FDA have public mandates and accountability, but also agency-wide industry-fee income. That is disclosed as an institutional indirect tie. It does not establish that a DGL company paid for the particular guidance quoted here. EMA funding, FDA fee system
Documented financial relationships
The relationships below include source links and unresolved financial or design-role questions. Geographic labels identify operations or study sites, not individual citizenship.
The relationships show documented roles, financing or product sources. A product-source relationship does not mean a donation. No ownership percentage is assigned where a current primary record was unavailable (Reported company role; Conflicting role statements; Dated ownership record).
Reported relationships:
- Natural Remedies, India → develops and sells → GutGard (Maker/product identity).
- Anurag and Amit Agarwal → documented leadership roles → Natural Remedies; no equity percentages inferred (Leadership operating roles).
- Natural Remedies → company authors and randomization → Raveendra dyspepsia research (Author affiliations and randomization).
- Natural Remedies → documented sponsorship and reported protocol input → Raj reflux research; the funding and acknowledgment statements conflict on the design role (Actual conflicting declarations).
- Natural Remedies → company coauthors → Puram H. pylori research (Company coauthors).
- NICS, South Korea → financial assistance and company coauthor → Puram research (NICS support and Seoul affiliation).
- GutGard → dated commercial distribution records → AIDP, United States; current contractual rights and royalties remain unverified (Dated sheet; Historical arrangement; US corporate office).
- NIH, United States → public grants → Liu interaction study (Actual public grants).
- Natural Remedies → original extract source → Liu study; purchase or donation unresolved (Extract source; no transaction statement).
- Shimadzu Scientific Instruments, United States → mass spectrometer provided → Liu study; terms unspecified (Instrument acknowledgment; US entity and Japanese parent).
- Shahrekord University, Iran → declared funding → Momeni combination trial; purchasing terms unresolved (Research Deputy support).
- Boehringer Ingelheim, Germany → acknowledged Ulcedal/placebo supply → Bardhan trial, United Kingdom; payment terms unresolved (Acknowledged supply and UK site; German corporate headquarters).
- Natural Remedies → Natural Living, India; the credit report records 100% ownership at 31 March 2025, without identifying this as a GutGard trial-funding route (Actual March 2025 subsidiary table).
How this changes the verdict
Funding does not prove a false result. Under this review’s stated commercial-exclusion rule, manufacturer or seller outcome research is reported as context and does not supply the independent benefit verdict. A brand name alone does not demonstrate sponsorship, and an arm’s-length purchase would not itself establish sponsorship. Actual declarations, company authors, material supply and study support are assessed separately; missing terms remain unknown (Direct manufacturer role; Declared sponsor; Product supply; Operational and statistical support).
The modern branded studies reviewed here are mainly from India, with additional studies in Iran and South Korea and historical clinical work in Sweden, Israel and the United Kingdom. Location is not a quality score. Direct company roles, study support and unresolved financial terms determine the funding screen (Indian study; Iranian study; Korean study; Swedish study; Israeli study; UK study).
Regulatory status
United States
Dietary supplements are not FDA-approved for safety or effectiveness before sale. A facility registration, lawful sale or food-use safety determination does not establish an approved treatment for ulcers, GERD or H. pylori infection. FDA distinguishes structure/function statements from disease-treatment claims, which bring a product within drug regulation. FDA supplement questions and answers
European Union
EMA published its revised licorice-root assessment and herbal monograph in July 2026. The assessment’s traditional-use framework and its criticism of the clinical evidence must not be presented as a broad authorization for every DGL extract or branded digestive claim. The preparation and national product authorization matter. EMA document record, 2026 assessment
Canada
Health Canada’s DGL monograph, dated 31 January 2025, supports a natural-health-product licensing route for specified demulcent digestive claims. It requires chewable forms mixed with saliva. Its specification allows no more than 3% of the original quantity of glycyrrhizic acid in the source material. That is different from a limit of 3% by weight of the finished extract. The monograph is industry licensing guidance, explicitly not a comprehensive evidence review. Canadian DGL monograph
This regulatory route does not establish an independently replicated treatment effect under this article’s stricter evidence screen. Health Canada’s institutional funding includes public appropriations and regulatory revenues. Departmental financial statements
This summary does not establish the status of every product in every jurisdiction. A clinical paper, trademark and regulatory authorization answer different questions (US scope; Canadian licensing conditions; EU document scope).
Frequently asked questions
Does DGL mean completely glycyrrhizin-free?
Not necessarily. Published preparations are described with residual limits, and the GutGard reports themselves contain differing specifications. The useful information is the tested content of the particular extract and batch (Earlier specification; Different reported specification; Different regulatory metric).
Is GutGard the same as generic DGL?
GutGard is a specific proprietary preparation. A generic DGL product should not inherit its study results without evidence of relevant compositional and clinical equivalence (Commercial identity; Specific tested extract).
Does an improvement in heartburn prove an ulcer or infection has healed?
No. Symptoms, tissue healing and infection status are separate outcomes. Each requires the appropriate assessment (Symptoms without healing; On-treatment tests; Follow-up testing).
Why does the verdict remain uncertain despite positive trials?
The positive findings are reported, but major studies have commercial involvement. This review deliberately asks what is established after excluding those outcomes from its independent benefit basis. Remaining unknown funding and formulation differences also matter (Manufacturer authors; Declared sponsorship; Same underlying trial).
Can DGL replace a PPI, antibiotics or bismuth?
The audited evidence does not establish that replacement. It does not support changing a prescribed regimen based on these supplement studies (Combination not equivalence; Clinical cause-directed care).
Must DGL be chewed?
Canada’s cited licensing monograph requires chewing. Different clinical research programs used different formulations, and a convincing independent head-to-head comparison was not identified. Regulatory directions and evidence of comparative efficacy are separate questions (Canadian chewable condition; Historical mixed tablet; Modern capsule).
Is it safe with every medicine if glycyrrhizin is low?
That has not been demonstrated. The human interaction study examined four metabolic pathways for one extract under short, controlled conditions. Residual glycyrrhizin and other constituents still require attention (Specific fasting pathway test; Broader exposure warnings).
Sources and funding notes
Tier 1 means no identifiable subject-related stake after the stated checks; Tier 2 means indirect ties; Tier 3 means an interested party; Tier 4 means maker/seller production, sponsorship or demonstrated in-kind support. Unknown is not forced into a tier. Grades A–D describe credibility for the stated use: A high, B solid with limitations, C materially interested, D directly self-interested. These judgments describe provenance and incentives, not a guarantee that any result is true or false.
| Source | Funding, ownership or revenue and country | Tier and grade | Accuracy incentive and limitation |
|---|---|---|---|
| Raveendra 2012 | Natural Remedies authors and trial role; India; complete cash/procurement ledger absent | 4 / D for outcomes | Peer-reviewed methods; manufacturer stakes and small sample |
| Raj 2025 | Natural Remedies sponsored and supplied products; India; no author conflicts declared | 4 / C | Funding paragraph reports design/protocol input, acknowledgments deny design involvement. Attrition, short follow-up and specification discrepancy remain |
| Puram 2013 | NICS funds, Korea; Natural Remedies authors, India; owners unresolved | 4 / D for outcomes | Controlled report; on-treatment tests and per-protocol analysis |
| Engqvist 1973; Complete original | Stockholm clinical team, Sweden; Cedona Holland supplied DGL capsules; cash and purchase/donation terms unreported | Commercial product source verified; transaction tier unresolved / B provisional | Full five-page original read; null radiological-healing result. No separate financing or COI declaration identified |
| Feldman 1971; Complete original | Ichilov Hospital, Tel Aviv, Israel; Cedona Haarlem supplied Caved-S; cash and transaction terms unreported | Commercial product source verified; transaction tier unresolved / B provisional | Full three-page original read; 50 started, 47 analyzed; symptom-only comparison in a multi-ingredient preparation |
| Bardhan 1978; Complete original | UK clinical team; Boehringer supplied active/placebo; Ulcedal prepared by Cedona, Netherlands; transaction terms unreported | Commercial supply verified; purchase/donation tier unresolved / B provisional | Complete four-page original read; null benefit and one edema/hypokalemia event. No separate cash or COI statement identified |
| Morgan 1982; Complete original | Airedale UK clinical study; no separate cash funding, material transaction or author COI statement identified | Unknown / B provisional | 117 entered, 100 analyzed; single-blind combination comparison. Nonsignificance does not establish equivalence |
| Morgan 1985 | UK trial; Glaxo Group Research and Tillotson Laboratories supported operation; Glaxo performed statistical analyses | 4 for declared commercial study support / C | Complete original read; cash amounts and product purchase/donation terms not itemized; null add-on result, not isolated DGL |
| Momeni 2014 | Shahrekord Research Deputy support, Iran; no COI declared; Irandaruc product, transaction terms unreported | Unknown overall / B provisional | Complete main original read; missing batch specification, unclear regimen duration and no equivalence margin |
| Hajiaghamohammadi 2016 | Qazvin academic/hospital authors, Iran; no COI declared; cash and product transaction terms unreported | Unknown / B provisional | Complete original outcome table and disclosures read; narrative/table counts and post-treatment testing timing differ or remain unclear |
| Yoon 2019 | South Korean hospital/university study; no funding declared; Korea Yakult product development | Unknown / B provisional | Reports between-group results; no procurement terms, combination intervention |
| Liu 2023 | NIH ODS/NCCIH P50AT000155 and NCATS UL1TR002003, US; no author conflicts declared; Natural Remedies extract and Shimadzu instrument, transaction terms unreported | Unknown overall; Tier 2 equipment input / B provisional | Complete main original read; 14 completers, 150 mg/day, fasting four-pathway probe study. Does not test all doses, preparations or simultaneous-use short-lived inhibition |
| Li 2016 analytical study | US university/NIH grants; retail materials purchased; reference-standard gift and Shimadzu instrument provision, terms unspecified | 2 provisional / B for identity methods | Reproducible chemistry; equipment-industry tie; not an outcome trial or market-wide audit |
| Cochrane 2023 review | University support, Chile/Germany; no external support or known conflicts declared; UK charitable publisher | 1 provisional at review level / B | Transparent synthesis; incomplete trial-level commercial classification |
| Kim 2013 animal study | KHIDI and NCEED grants, South Korea; maker extract, procurement unknown | Unknown / B provisional for mechanism | Experimental methods; underlying institutional ties not fully resolved; excluded from human conclusions |
| Bhide 2022 rat study | Natural Remedies R&D/regulatory authors; India; full cash budget unspecified | 4 / D for human safety promotion | Published toxicology; animal-to-human extrapolation inappropriate |
| NCCIH licorice information | NIH public agency, Bethesda, US; appropriations | 1 provisional / A for safety context | Public-health mandate and references; broad licorice guidance, not a batch audit |
| NCCIH appropriations | US federal funding record | 1 / A for funding | Public fiscal accountability; not evidence about a supplier transaction |
| NIDDK ulcer treatment | NIH, US public health publication | 1 provisional / A for clinical context | Expert-reviewed public information; not DGL efficacy research |
| NIDDK reflux symptoms | NIH, US public health publication | 1 provisional / A for warning signs | Public-health mandate; individual diagnosis remains outside its scope |
| NHS chest-pain guidance | UK publicly funded health service; public clinical information | 1 / A for emergency guidance | Public safety accountability; not DGL-specific efficacy or incidence evidence |
| EMA 2026 assessment | EU medicines agency, Netherlands; public budget and industry fees | 2 institutionally / A for assessment record | Public reasoning and regulatory accountability; underlying research retains its conflicts |
| EMA document register | Same agency and EU jurisdiction | 2 / A for dates and status | Authoritative current document record; not product-specific approval |
| EMA funding page | EU agency; industry fees and EU contribution; Netherlands | 2 / A for institutional facts | Actual current budget disclosure read; agency-wide financing does not establish DGL-specific guidance payment |
| FDA supplement Q&A | US agency; appropriations and agency-wide user fees | 2 institutionally / A for regulatory scope | Legal mandate; no DGL outcome endorsement |
| FDA user-fee explanation | US federal regulatory financing | 2 / A for funding system | Direct statutory explanation; no specific licorice-payment inference |
| Health Canada DGL monograph | Canadian federal agency, Ottawa; public funds and agency-wide regulatory revenue | 2 institutionally / A for licensing conditions | Direct official wording; underlying traditional references are not an independently screened trial set |
| Health Canada financial statements | Canadian government departmental accounts; marked unaudited | 2 / A for institutional funding record | Fiscal accountability; no product-specific payment or influence inferred |
| Natural Remedies GutGard page | Ingredient seller, India; private ownership chain unresolved | 4 / C for identity, D for efficacy/safety marketing | Direct product knowledge; promotional breadth exceeds clinical evidence |
| Natural Remedies leadership | Company self-description, India | 4 / C for named roles | Direct operational knowledge; leadership does not establish equity |
| CARE Ratings 2025 report | Indian rating agency; primarily issuer-paid model; public-company ownership not fully traced here | 4 / C for corporate context | Credit-market accountability; commercially produced assessment, not an audit; specific fee amount unknown |
| AIDP dated sales sheet | Commercial distributor; US corporate office; current ultimate owners unresolved | 4 / C for dated offering; D for outcomes | Complete original one-page sheet read through public web; trial-duration description differs from original, current contract unverified |
| Natural Remedies distribution announcement | Manufacturer-origin publicity; India/US commercial relationship; hosted newsletter | 4 / C for historical arrangement | Attributed corporate statement; current contract not inspected |
| Caved-S 1983 advertisement | Tillotts Laboratories seller copy, UK; historical ownership not traced | 4 / C for ingredients, D for claims | Contemporary label record; journal hosting does not make it editorial evidence |
| April 1979 Caved-S advertisement | Historical seller-origin material; exact April PDF was not recovered | 4 / C for source provenance; exact document access unresolved | Earlier composition is verified from the complete 1971 original rather than treating an unavailable advertisement as personally read |
| Cochrane 2024 accounts | UK charity; Wiley royalties, products, events, consultancy and grants | 1 relative to DGL / A for institutional finances | Statutory accounts and audit; not an audit of all review authors’ institutions |
| NLM carbenoxolone record | US National Library of Medicine primary vocabulary | 1 provisional / A for chemical identity | Direct identity/entry terms; no current drug-authorization or outcome inference |
| ASGE food-obstruction guidance | US professional society; consultants to Boston Scientific, Facet Biotech and Fujinon declared; remaining authors declared no relevant ties | 2 for disclosed indirect ties / B for narrow warning | Original indexed airway/timing/recommendations/disclosures read; full PDF unavailable; separate cash budget not reported |
| Shimadzu corporate identity | US operating entity; Japanese parent identified; commercial instrument seller | 4 / C for own corporate identity | Official headquarters/parent statement; Liu instrument acknowledgment read separately; payment terms unknown |
| Boehringer headquarters | Commercial drug manufacturer, Germany; indexed original headquarters section | 4 / C for own location | Supports country label only; historical Ulcedal supply verified in Bardhan, procurement terms unreported |
| AIDP corporate office | Commercial distributor, City of Industry, California, US | 4 / C for own office | Current official operating location; does not establish ultimate owners or current exclusive distribution contract |
| NHS vomiting-blood guidance | UK public clinical information | 1 provisional / A for warning signs | Urgent/emergency assessment guidance; no DGL-specific causal or incidence inference |
Scope and remaining gaps
This is a focused critical review of the sources cited here, not an exhaustive registered systematic review. Relevant original main Methods, results and disclosures were personally read for the human trials; complete historical Engqvist, Feldman, Bardhan and Morgan papers were recovered. The 1983 advertisement remains an indexed prescribing record, and the exact April 1979 advertisement and complete ASGE guideline PDF were not recovered. ASGE’s original indexed airway, timing, recommendation and disclosure sections support the narrow obstruction warning. Separate supplements, raw data, unreported finance, procurement terms, batch certificates, current beneficial owners and distribution contracts remain unresolved. No-conflict declarations or absent disclosures do not establish independence or misconduct.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
